ConnectiveRx vs EVERSANA: Hub Services Head-to-Head Comparison | Rx Almanac

---

Overview

The U.S. hub services market generates an estimated $1.5–1.8 billion in operator-fee revenue annually, growing at 7–9% CAGR driven by specialty pharmaceutical expansion. ConnectiveRx and EVERSANA represent opposite ends of the vendor spectrum — focused patient support specialist vs. full-stack commercialization partner — and both have compelling arguments for why their model wins.

Attribute	ConnectiveRx	EVERSANA
Headquarters	Whippany, NJ & Pittsburgh, PA	Milwaukee, WI
Founded	2015 (by Harry Totonis, via Genstar Capital)	2018 (roll-up of 10+ acquisitions)
Ownership	Kohlberg & Company (PE-backed since 2022)	Privately held; acquired Waltz Health in 2025, combined valuation ~$6B
CEO	Harry Totonis (founder; returned Jan 2023)	Jim Lang (CEO since 2017)
Est. Revenue	~$400–680M	~$1B+
Employees	~1,400	~5,000+
Pharma Customers	150+ manufacturers, 530+ brands, all top-20 pharma	670+ biopharma customers, 25 of top 25
Customer Retention	98% overall; 100%+ net revenue retention (Hub & A&A)	Not publicly disclosed
Core Identity	Focused patient support & affordability platform	Full-stack commercialization partner

---

Service Scope Comparison

Where They Overlap

Both vendors compete head-to-head in the core hub services market: benefit verification, prior authorization, patient enrollment, copay assistance, adherence programs, and nurse/case manager support. Both serve top-tier pharma clients across specialty therapeutic areas and offer technology-enabled call centers, provider portals, and patient engagement platforms.

Where ConnectiveRx Goes Deeper

• Copay Programs: ConnectiveRx’s copay segment (~$116M, 27% of revenue) is a mature, high-margin business with 96% retention and 71% gross margins. Processes copay cards at ~$2.50 per redemption at scale — a genuine cash cow with deep operational expertise.
• Awareness & Adherence Messaging: Operates one of the largest EHR-integrated prescriber networks in the industry, reaching 70%+ of U.S. HCPs. A&A segment generates ~$111M in revenue through point-of-care messaging at ~$2.00 per message — functions as a top-of-funnel patient acquisition engine for hub clients.
• Non-Commercial Pharmacy: Careform non-commercial pharmacy enables e-prescribing directly into the hub workflow, reducing enrollment friction. Expanded into full dispensing capabilities with ConnectiveRx Pharmacy in September 2025.

Where EVERSANA Goes Broader

• Full Commercialization Stack: Eight capability areas spanning advisory, agency (EVERSANA INTOUCH), field deployment, medical affairs, market access, pricing & reimbursement, patient services & specialty pharmacy, and trade/channel/3PL.
• Owned Specialty Pharmacy: URAC/ACHC/NABP-accredited specialty pharmacy in Chesterfield, MO (85,000+ shipments/year, 99% dispensing accuracy, 99.8% inventory accuracy). Provides enrollment-through-dispensing data continuity.
• Field Force Deployment: Contract sales teams — a capability ConnectiveRx does not offer.
• Regulatory & Market Access Consulting: Advisory services for pricing, reimbursement strategy, and HEOR through EVERSANA Consulting and the former Healthware Group.
• Waltz Health Integration: 2025 acquisition adds PBM transparency and employer-side drug pricing tools, positioning EVERSANA across both manufacturer and payer sides.

Is Broader Better?

When yes: For emerging biotechs launching their first product, a single vendor handling field force, market access, hub services, and specialty pharmacy dispensing can dramatically simplify commercialization. Integration reduces handoff friction and creates unified patient data.

When no: For established pharma with in-house commercial teams, buying bundled services means paying for unneeded capabilities — and potentially accepting a vendor whose hub operations are one division among many rather than the core focus. Broader scope can also introduce conflicts of interest (e.g., an owned specialty pharmacy has different incentives than a pharmacy-agnostic hub).

---

Technology Comparison

Dimension	ConnectiveRx	EVERSANA
Core Platform	Proprietary hub CRM (undergoing $5.2M re-platform investment), Careform portal, EDW ($2.9M investment)	ACTICS data platform (280M+ lives, 300M patient records, longitudinal claims/EHR/formulary data)
eBV/ePA	Electronic BV and PA via hub workflow	ACTICS eAccess: 90% eBV success rate vs. 43% industry avg; 92–96% ePA acceptance vs. 73% industry rejection rate
Automation	OCR automation ($3.4M projected savings), call bots ($1.3M savings), cross-training	ORCHESTRATE omnichannel platform with digital concierge, AI chatbot, ML-driven patient identification
Data Asset	EHR network reaching 70%+ of U.S. HCPs; prescriber behavior data from point-of-care messaging	ACTICS: 280M+ lives of longitudinal claims, EHR, and formulary data; ML engines for patient-finding and switch prediction
HCP Connectivity	Largest EHR aggregator network; integrations with Veradigm, Athena Health, Epic-connected systems	1,400+ payer connections for eBV; pharmacy/provider network integrations
DTP / Telehealth	ConnectiveRx Pharmacy (launched Sept 2025) for dispensing; limited telehealth	DTP via Upscript partnership (90K+ Rx shipped/year); telehealth = 20% of brand revenue in case studies; patient NPS 74

Who Has the Better Data Asset?

EVERSANA — and it is not close. ACTICS with 280M+ lives of longitudinal claims and EHR data is a qualitatively different asset than ConnectiveRx’s operational data. ACTICS enables predictive analytics (patient-finding, switch prediction, treatment journey modeling) that ConnectiveRx cannot replicate without a comparable investment. EVERSANA’s published eBV/ePA metrics (90% success rate, 92–96% acceptance) demonstrate the data advantage translating into operational outcomes.

Who Has the Better Operational Technology?

ConnectiveRx is competitive here despite smaller scale. Hub CRM re-platforming, OCR automation, and cross-training initiatives reflect a pragmatic, ROI-focused approach to operational efficiency. Its EHR network for prescriber messaging is a genuine differentiator — an awareness and adherence engine that also feeds hub enrollment. For pure hub operational workflow, ConnectiveRx’s focus means its hub technology evolves based entirely on hub use cases rather than competing for R&D dollars with eight other business lines.

---

Operational Model

ConnectiveRx: Dedicated FTE Model

• Staffing: Dedicated FTEs at ~$55K/head; typical programs range from 10–75 FTEs with $2–8M annual contracts
• Cross-Training: Currently 51% of FTEs cross-trained, targeting 70%+ to improve utilization (target: 85% utilization)
• Sweet Spot: Small-to-mid-tier programs where dedicated teams provide continuity and therapeutic expertise
• Margin Profile: 50% gross margin, 24% contribution margin, 18% FCF margin on hub — lean but with clear efficiency levers
• Pharmacy: Non-commercial Careform pharmacy for intake; new ConnectiveRx Pharmacy for dispensing (early-stage)

EVERSANA: Integrated Model with Owned Specialty Pharmacy

• Staffing: Blended model across hub, specialty pharmacy, and field teams; specific FTE economics not publicly disclosed
• Integration: Patient data flows from enrollment through dispensing without handoffs to external pharmacies — the core thesis of the integrated model
• Specialty Pharmacy: 85,000+ shipments/year with 99% accuracy; URAC/ACHC/NABP accredited — a real pharmacy, not a pass-through
• Breadth: Can deploy field reps, run market access consulting, and manage trade/channel alongside hub — a single MSA for the full commercial stack

Cost Structure Implications

ConnectiveRx’s transparent FTE-based pricing (dedicated teams at known per-head costs) makes budgeting predictable. EVERSANA’s bundled approach may offer economies of scope for multi-service buyers, but can be harder to unbundle for hub-only purchasers. Buyers should request detailed pricing breakdowns from EVERSANA to avoid paying an integration premium for services they don’t use.

Flexibility and Customization

ConnectiveRx’s focused model allows more program-level customization — its 40–50% competitive win rate suggests it frequently outmaneuvers larger competitors on tailored program design. EVERSANA’s breadth means more pre-built integrations but potentially less flexibility to customize individual components. For programs requiring unique workflow configurations, ConnectiveRx’s smaller, dedicated teams may be more responsive.

---

Financial Comparison

Metric	ConnectiveRx	EVERSANA
Revenue (est.)	~$400–680M	~$1B+
Revenue CAGR	~13% (2019–2022 documented)	Not publicly reported; aggressive acquisition-driven growth
EBITDA Margin	~32% (LTM Aug 2022)	Not publicly reported
FCF Conversion	~85% of EBITDA	Not publicly reported
Pricing Model	FTE-based (hub), per-transaction (copay at ~$2.50/card, A&A at ~$2.00/message)	Bundled; per-program and per-patient; outcomes-based options available
Typical Contract	Hub: $2–8M/year; Copay and A&A: shorter-cycle, transaction-based	Full commercial partnerships: multi-year, multi-service MSAs
Customer Concentration	Top customer (Novo Nordisk) at 13%; top 5 at ~45%; top 10 at ~65%	Not publicly disclosed; likely more diversified given 670+ customers
LOE Risk	22% of 2022 revenue from drugs with LOE in 2022–2024 window	Broader portfolio likely reduces single-drug LOE exposure
Retention	98% customer retention; churn primarily LOE-driven	Not publicly disclosed

Key Financial Takeaway

ConnectiveRx offers significantly more financial transparency — its PE ownership structure means detailed financial data is available through IC memos and lender materials. EVERSANA discloses less as a private company built through acquisitions. For buyers negotiating contracts, ConnectiveRx’s per-unit economics are clearer and easier to benchmark. EVERSANA’s pricing requires more diligence to decompose, particularly when purchasing only a subset of its services.

---

Best-For Scenarios

ConnectiveRx Is Best For:

• Mid-size biotechs wanting focused hub + copay without buying a full commercialization suite. Sweet spot is the $2–8M program with dedicated FTEs who develop deep therapeutic expertise.
• Pharma brands prioritizing prescriber engagement alongside patient support. The EHR-integrated awareness network (70%+ of U.S. HCPs) is a differentiated asset no pure hub competitor can match.
• Cost-conscious programs needing transparent pricing. FTE-based and per-transaction models make budgeting predictable.
• Established pharma with in-house commercial teams that need a best-of-breed hub and copay partner, not a second commercial infrastructure.
• Brands with strong existing specialty pharmacy relationships that want a pharmacy-agnostic hub partner rather than one with an owned pharmacy that may steer volume.

EVERSANA Is Best For:

• Emerging biotechs launching their first product that need a single partner for field force, market access, hub services, and specialty pharmacy. EVERSANA can take a molecule from pre-launch strategy through steady-state dispensing.
• Programs requiring owned specialty pharmacy with enrollment-to-dispensing data continuity. Ideal for closed distribution models or maximum patient journey control.
• Data-intensive programs that benefit from ACTICS’ 280M+ lives of longitudinal data for patient-finding, switch prediction, and RWE generation.
• Global or multi-market launches where EVERSANA’s international presence (agency network, consulting, regulatory) adds value beyond U.S. hub services.
• Brands wanting outcomes-based commercial partnerships where the vendor shares risk — EVERSANA has piloted models with compensation tied to commercial performance.

Neither Is Best For:

• Large pharma wanting distributor-integrated hub services: Look at Cencora/Lash Group or McKesson, where hub services sit within the specialty distribution infrastructure. Note: Cencora classified its legacy U.S. hub services as non-core in Q1 FY2026, signaling potential divestiture.
• Programs demanding maximum technology-first, API-driven hub architecture: Consider CareMetx (General Atlantic-backed) or AssistRx (WCAS-backed since 2024), both positioning as digital-first platforms with deeper API and EHR integration.
• Biosimilar or mature brand programs seeking lowest-cost hub operations: Neither vendor optimizes for the price-sensitive end of the market; smaller regional providers or in-house solutions may be more appropriate.

---

Comparison Matrix

Ratings on a 1–5 scale (5 = best in class; 3 = market average).

Dimension	ConnectiveRx	EVERSANA	Notes
Hub Services Breadth	4	4	Both strong; ConnectiveRx slightly more focused, EVERSANA integrates with pharmacy
Technology / Data Platform	3	5	ACTICS is a generational data asset; ConnectiveRx’s EHR network is strong but narrower
Copay / Financial Assistance	5	3	ConnectiveRx’s copay segment is a standalone best-in-class business
Specialty Pharmacy Capability	2	5	EVERSANA owns and operates an accredited specialty pharmacy; ConnectiveRx just launched dispensing
Scalability (Small to Large)	4	4	ConnectiveRx proven for small/mid; EVERSANA for large/complex — both scale within their lanes
Pricing Flexibility	4	3	ConnectiveRx’s unbundled, per-unit pricing is easier to benchmark and negotiate
Therapeutic Area Depth	4	4	Both serve broad TA portfolios; EVERSANA’s pharmacy adds depth in rare disease
Innovation / R&D Investment	3	4	EVERSANA invests more broadly (ACTICS, ORCHESTRATE, Waltz Health); ConnectiveRx’s R&D is operationally focused
Independence / Conflict-Free	5	3	ConnectiveRx is pharmacy-agnostic (historically); EVERSANA’s owned pharmacy creates potential channel bias
Implementation Speed	4	3	Smaller, focused teams typically onboard faster; EVERSANA’s integrated model has more moving parts
Composite	38/50	38/50	Tied — genuinely well-matched overall, with advantages in different dimensions

---

Verdict / Decision Framework

There is no universally “better” vendor. The right choice depends on the buyer’s situation, clarified by three questions:

Question 1: Do you need a commercialization partner or a patient support vendor?

If you have an in-house commercial team and need a best-in-class hub, copay, and prescriber engagement partner — ConnectiveRx. If you need a vendor that can own or supplement your entire commercial operation from field force to dispensing — EVERSANA.

Question 2: How important is owned specialty pharmacy capability?

If your product requires closed distribution, direct-to-patient fulfillment with integrated data, or enrollment-to-dispensing continuity under one roof — EVERSANA’s owned pharmacy is a genuine differentiator. If you prefer pharmacy-agnostic hub services that work with any SP network — ConnectiveRx preserves optionality (though its new dispensing capability is narrowing this gap).

Question 3: What stage is your brand and your company?

Pre-launch emerging biotech with limited infrastructure — EVERSANA can be your outsourced commercial engine. Established pharma adding a new specialty brand to an existing portfolio — ConnectiveRx drops into your existing infrastructure with less disruption and more transparent economics.

The Bottom Line

ConnectiveRx is a focused, high-margin, operationally excellent patient support platform that wins on specialization, pricing transparency, and prescriber network reach. EVERSANA is a full-stack commercialization platform that wins on breadth, data depth, and integrated pharmacy. Both are credible choices for hub services — but they serve different buyer archetypes. The best decision is the one that matches your organizational reality, not a vendor capability deck.

---

Sources

• PE investment committee memos (Kohlberg & Company, Oct–Nov 2022)
• EVERSANA capabilities presentations (2024)
• Company press releases and public filings
• Third-party market research (Grand View Research, Growjo, Prospeo)
• Raw source: connectiverx-vs-eversana-comparison.md